Advisors Llcperceptive Life... Net Worth

The estimated Net Worth of Advisors Llcperceptive Life... is at least $120 Million dollars as of 12 August 2024. Advisors Life owns over 1,250,000 units of Athira Pharma stock worth over $6,140,240 and over the last 7 years Advisors sold ATHA stock worth over $113,427,336.

Advisors Life ATHA stock SEC Form 4 insiders trading

Advisors has made over 133 trades of the Athira Pharma stock since 2017, according to the Form 4 filled with the SEC. Most recently Advisors bought 1,250,000 units of ATHA stock worth $5,000,000 on 12 August 2024.

The largest trade Advisors's ever made was buying 20,000,000 units of Athira Pharma stock on 23 September 2019 worth over $10,000,000. On average, Advisors trades about 1,250,084 units every 18 days since 2017. As of 12 August 2024 Advisors still owns at least 12,531,103 units of Athira Pharma stock.

You can see the complete history of Advisors Life stock trades at the bottom of the page.

Insiders trading at Athira Pharma

Over the last 4 years, insiders at Athira Pharma have traded over $100,296 worth of Athira Pharma stock and bought 5,411,219 units worth $62,123,025 . The most active insiders traders include Advisors Llcperceptive Life..., Investments, Lpwong Roderic..., and Joseph Edelman. On average, Athira Pharma executives and independent directors trade stock every 33 days with the average trade being worth of $62,547. The most recent stock trade was executed by Andrew Gengos on 3 September 2024, trading 1,272 units of ATHA stock currently worth $725.

What does Athira Pharma do?

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Complete history of Advisors Life stock trades at Acelrx Pharmaceuticals Inc, Adma Biologics Inc, Agile Therapeutics Inc, Albireo Pharma Inc, Aldeyra Therapeutics Inc, Amicus Therapeutics Inc, Athenex Inc, Global Blood Therapeutics, La Jolla Pharmaceutical Co, Leap Therapeutics Inc, Quotient Ltd, Scynexis Inc, Soleno Therapeutics Inc, VBI Vaccines, Zogenix Inc, Kadmon Inc, Solid Biosciences Inc, Menlo Therapeutics, Motus GI Inc, MeiraGTx plc, Verrica Pharmaceuticals Inc, Crinetics Pharmaceuticals Inc, ARYA Sciences Acquisition Corp III, ARYA Sciences Acquisition Corp II, and Athira Pharma

Athira Pharma executives and stock owners

Athira Pharma executives and other stock owners filed with the SEC include:

• Dr. Hans Moebius,
  Chief Medical Officer
• Glenna K. Mileson,
  Chief Financial Officer
• Dr. Kevin Church Ph.D.,
  Exec. VP of Research
• Mark F. Worthington J.D.,
  Gen. Counsel & Corp. Sec.
• Julie Rathbun,
  Head of Investor Relations
• Robert Renninger,
  Director of Accounting & Reporting
• Rachel P. Lenington M.B.A.,
  Chief Operating Officer
• Dr. Mark J. Litton M.B.A., MBA, Ph.D.,
  Pres, CEO & Director
• James A Johnson,
  
• Kelly A Romano,
  
• Rachel Lenington,
  COO and CDO
• Michael A. Panzara,
  
• Kevin Church,
  CHIEF SCIENTIFIC OFFICER
• Advisors Llcperceptive Life...,
  
• Investments, Lpwong Roderic...,
  
• Martin Javier San,
  CHIEF MEDICAL OFFICER
• John M Jr Fluke,
  
• Advisors Llcperceptive Life...,
  
• Barbara Kosacz,
  
• Leen Kawas,
  President & CEO
• Hans Moebius,
  Chief Medical Officer
• Glenna Mileson,
  Chief Financial Officer
• Tadataka Yamada,
  Director
• Mark Worthington,
  GENERAL COUNSEL
• Joseph Edelman,
  
• Grant Pickering,
  
• Mark James Litton,
  President and CEO